|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | National Heart, Lung, and Blood Institute (NHLBI) |
|---|---|
| Information provided by: | National Heart, Lung, and Blood Institute (NHLBI) |
| ClinicalTrials.gov Identifier: | NCT00000516 |
Purpose
To determine if enalapril treatment of left ventricular dysfunction (LVD) due to ischemic or hypertensive heart disease led to reduced mortality and morbidity in symptomatic and asymptomatic patients. There were a Prevention Trial, a Treatment Trial, and a registry.
| Condition | Intervention | Phase |
|---|---|---|
|
Cardiovascular Diseases Coronary Disease Heart Diseases Heart Failure Hypertension Myocardial Ischemia |
Drug: enalapril |
Phase III |
| Study Type: | Interventional |
| Study Design: | Prevention, Randomized, Double-Blind, Placebo Control |
Eligibility| Ages Eligible for Study: | 21 Years to 80 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Men and women, ages 21 to 80. Subjects were asymptomatic or symptomatic and had ejection fractions equal to or below 35 percent.
Contacts and Locations
More Information
| Study ID Numbers: | 35 |
| Study First Received: | October 27, 1999 |
| Last Updated: | June 23, 2005 |
| ClinicalTrials.gov Identifier: | NCT00000516 History of Changes |
| Health Authority: | United States: Federal Government |
|
Arterial Occlusive Diseases Ventricular Dysfunction Heart Failure Heart Diseases Molecular Mechanisms of Pharmacological Action Myocardial Ischemia Vascular Diseases Enzyme Inhibitors Cardiovascular Agents Ischemia Arteriosclerosis Antihypertensive Agents |
Pharmacologic Actions Protease Inhibitors Coronary Disease Enalapril Pathologic Processes Therapeutic Uses Angiotensin-Converting Enzyme Inhibitors Ventricular Dysfunction, Left Cardiovascular Diseases Coronary Artery Disease Hypertension |